Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade
Oncogene, 2013•nature.com
Monoclonal antibodies against the epidermal growth factor receptor (EGFR) are effective
cancer therapeutics, but tumors harboring RAS mutations are resistant. To functionally
dissect RAS-mediated resistance, we have studied clinically approved anti-EGFR
antibodies, cetuximab and panitumumab, in cancer models. Both antibodies were equally
cytotoxic in vitro. However, cetuximab, which also triggers antibody-dependent cellular
cytotoxicity (ADCC), was more effective than panitumumab in vivo. Oncogenic RAS …
cancer therapeutics, but tumors harboring RAS mutations are resistant. To functionally
dissect RAS-mediated resistance, we have studied clinically approved anti-EGFR
antibodies, cetuximab and panitumumab, in cancer models. Both antibodies were equally
cytotoxic in vitro. However, cetuximab, which also triggers antibody-dependent cellular
cytotoxicity (ADCC), was more effective than panitumumab in vivo. Oncogenic RAS …
Abstract
Monoclonal antibodies against the epidermal growth factor receptor (EGFR) are effective cancer therapeutics, but tumors harboring RAS mutations are resistant. To functionally dissect RAS-mediated resistance, we have studied clinically approved anti-EGFR antibodies, cetuximab and panitumumab, in cancer models. Both antibodies were equally cytotoxic in vitro. However, cetuximab, which also triggers antibody-dependent cellular cytotoxicity (ADCC), was more effective than panitumumab in vivo. Oncogenic RAS neutralized the activity of both antibodies in vivo. Mechanistically, RAS upregulated BCL-XL in cancer cell lines and in primary colorectal cancers. Suppression of BCL-XL by short hairpin RNA or treatment with a BH3 mimetic overcame RAS-mediated antibody resistance. In conclusion, RAS-mutant tumors escape anti-EGFR antibody-mediated receptor blockade as well as ADCC in vivo. Pharmacological targeting of RAS effectors can restore sensitivity to antibody therapy.
nature.com